Madrigal Pharmaceuticals, Inc.
MDGLNext catalyst
Resmetirom
NASH
Get an email about MDGL's next catalysts
Track Madrigal Pharmaceuticals (MDGL) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Resmetirom Phase 3 Est. Readout
Primary completion for Resmetirom trial (NCT05500222) in NASH
SourceResmetirom Phase 3 Est. Readout
Primary completion for Resmetirom trial (NCT04951219) in Non-Alcoholic Fatty Liver Disease
SourceHow MDGL's past catalysts played out
Market Overview
Stock performance and key metrics
Resmetirom
NASH
MGL-3196
Heterozygous Familial Hypercholesterolemia
MGL-3196 (resmetirom)
Heterozygous Familial Hypercholesterolemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Resmetirom | Phase 3 | NASH | - | - |
MGL-3196 | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
MGL-3196 (resmetirom) | Phase 2 | Heterozygous Familial Hypercholesterolemia | - | - |
NASH
1 drug in this indication
Heterozygous Familial Hypercholesterolemia
1 drug in this indication
Non-Alcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Madrigal Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Madrigal Pharmaceuticals, Inc.'s (MDGL) pipeline across Phase 3, Phase 2. Its lead program is Resmetirom (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Madrigal Pharmaceuticals, Inc.'s next FDA catalyst?β
Madrigal Pharmaceuticals, Inc.'s (MDGL) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MDGL biotech catalysts?β
Add MDGL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Madrigal Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
